BioVeris
This article was originally published in The Gray Sheet
Executive Summary
Settlement pact resolves all outstanding disputes between the firm and Meso Scale Diagnostics (MSD) - a joint venture between BioVeris and Meso Scale Technologies (MST) - as well as with MST CEO Jacob Wohlstadter. The deal includes a $5 mil. payment to MSD and an agreement for MSD or MST to purchase BioVeris' interest in MSD. BioVeris also gained sales data on the joint venture needed to file financial statements. The firm's delay in filing a 10-K for fiscal 2004 (ended March 31) with the SEC led to a July Nasdaq delisting notice (1"The Gray Sheet" July 26, 2004, p. 11)...